VanEck Associates
MRVI icon

VanEck Associates’s Maravai LifeSciences MRVI Stock Holding History

VanEck Associates’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,172
Closed -$2K – 1473
2025
Q3 		$2K Hold
1,172
– – ﹤0.01% 1421
2025
Q2 		$2K Sell
1,172
-1,681
-59% -$3.53K ﹤0.01% 1386
2025
Q1 		$6K Hold
2,853
– – ﹤0.01% 1373
2024
Q4 		$16K Buy
2,853
+1,266
+80% +$8.15K ﹤0.01% 1349
2024
Q3 		$12K Sell
1,587
-1,266
-44% -$10.9K ﹤0.01% 1334
2024
Q2 		$20K Hold
2,853
– – ﹤0.01% 1326
2024
Q1 		$25K Buy
2,853
+529
+23% +$3.58K ﹤0.01% 1311
2023
Q4 		$15K Buy
2,324
+318
+16% +$2.05K ﹤0.01% 1338
2023
Q3 		$20K Sell
2,006
-167
-8% -$1.83K ﹤0.01% 1334
2023
Q2 		$27K Buy
2,173
+294
+16% +$3.97K ﹤0.01% 1340
2023
Q1 		$26K Buy
1,879
+198
+12% +$2.84K ﹤0.01% 1343
2022
Q4 		$24K Sell
1,681
-2,799
-62% -$44.1K ﹤0.01% 1350
2022
Q3 		$114K Buy
4,480
+1,621
+57% +$40.7K ﹤0.01% 1158
2022
Q2 		$81K Buy
+2,859
New +$90.6K ﹤0.01% 1252

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VanEck Associates's MRVI Position: Q4 2025 in Review

VanEck Associates sold out of Maravai LifeSciences (MRVI) in Q4 2025, closing a stake of 1,172 shares — an estimated $2K sold.

VanEck Associates first reported a position in MRVI in Q2 2022 and held it in 14 quarters. The position peaked at $114K in Q3 2022. 159 funds tracked by Wall St. Rank hold MRVI as of Q4 2025.

  • VanEck Associates reported no remaining Maravai LifeSciences position as of Q4 2025 after selling out during the quarter.
  • VanEck Associates sold 1,172 Maravai LifeSciences shares in Q4 2025, an estimated $2K.
  • VanEck Associates first reported a position in Maravai LifeSciences in Q2 2022 and held it in 14 quarters.
  • VanEck Associates's Maravai LifeSciences position peaked at $114K in Q3 2022.
  • 159 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2025.

Based on VanEck Associates's 13F filing for Q4 2025, filed 13 Feb 2026.